[September 05, 2011]

Research and Markets: Congenital Heart Disease Pipeline Review, Q2 2011 - Gain a Snapshot of the Global Therapeutic Scenario for Congenital Heart Disease

Research and Markets (http://www.researchandmarkets.com/research/e0a89e/congenital_heart_d) has announced the addition of Global Markets Direct's new report "Congenital Heart Disease - Pipeline Review, Q2 2011" to their offering.

Global Markets Direct's, 'Congenital Heart Disease - Pipeline Review, Q2 2011', provides an overview of the Congenital Heart Disease therapeutic pipeline. This report provides information on the therapeutic development for Congenital Heart Disease, complete with latest updates, and special features on late-stage and discontinued rojects. It reviews key players involved in the therapeutic development for Congenital Heart Disease.

'Congenital Heart Disease - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

• A snapshot of the global therapeutic scenario for Congenital Heart Disease.
• A review of the Congenital Heart Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery to registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Congenital Heart Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy:

• Identify and understand important and diverse types of therapeutics under development.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

Companies Mentioned Include:

• Mesoblast Ltd
• CSL Limited
• Genetrix SL
• Asklepion Pharmaceuticals, LLC.

For more information visit http://www.researchandmarkets.com/research/e0a89e/congenital_heart_d

[ Back To TMCnet.com's Homepage ]